At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 406 enrolled
Drug / intervention
Vehicle of Loteprednol Etabonate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
In Brief
A Phase 3 clinical trial evaluating Vehicle of Loteprednol Etabonate and Loteprednol Etabonate for Inflammation and Pain. Completed, enrolled 406 participants across 1 site.
Detailed Summary
This study is being conducted to compare the safety and efficacy of loteprednol etabonate compared to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation, Pain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedNov 2009
Primary CompletionJun 2010
Study CompletionAug 2010
TodayJul 2026
First PostedNov 10, 2009
Enrollment StartNov 1, 2009
Primary CompletionJun 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.6 years ago
Interventions
Vehicle of Loteprednol Etabonatedrug
1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
Loteprednol Etabonatedrug
1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.